Projects IrsiCaixa is involved in a hundred national and international research projects active each year, funded by both public and private entities. Breadcrumb Home Projects Keywords Research group - Any -Cell Virology and Immunology (VIC)HIV and HVC Genetic and Phenotypic VariabilityImmunology (IGG)Microbial Genomics (GEM)Neoantigens and Vaccines against Cancer (NeoVaCan)Pathogen Immunity, Signalling and Therapeutic Applications (PISTA)Retrovirology and Clinical Studies (GREC)T-cell Immunology and Vaccines (TIV)Tissue Virology (VITI)Translational Research in Immunology and Ageing (TRIA)Viral Immune Evasion and Vaccines (VIRIEVAC)Virus-Host Interactions (ViHIT) Researcher - Any -Aleix Elizalde TorrentAlejandro Riquelme GrauAlessandra BorgognoneAlex Olvera van der StoepAna Barajas MolinaAnaí Villanueva DelgadoAnna López PlanaAnna Pons GrifolsArnau Creus OrodeaBeatriz Mothe PujadasBenjamin TrinitéBonaventura Clotet SalaCarla Rovirosa MartíCarlos Ávila NietoCarmen Aguilar GurrieriCecilia Cabrera NavarroChristian BranderCristina GálvezCristina Mesa RealCristina Peligero CruzCristina Ramírez SotoDaniela Benítez CanoDaniel Pérez ZsoltDàlia Raïch ReguéEdurne García VidalEdwards Pradenas SaavedraElena Lapaz LorenzoElisabet Fernández RosasElisabet García RodríguezElisa Molina MolinaErola Ainsua EnrichEster Ballana GuixEudald Felip FalgàsEudald Vehí PiquéEulalia Grau SegúEva Riveira MuñozFernando Laguía NuedaFerran Abancó i EspugaFrancesc Català MollFrancisco M. Muñoz LópezGabriel Felipe Rodríguez LozanoGerard Campos GonzalezGustavo Rodríguez EstebanIgnasi Calba IñiguezIgor Moraes CardosoIrene González NavarroItziar Erkizia JauregiJakub ChojnackiJavier Martínez-PicadoJoan Pagès OliverasJon Izquierdo PujolJordi Senserrich VelascoJorge Carrillo MolinaJosé Luis Pérez GuillamónJudith Dalmau MorenoJulia García PradoJulieta CarabelliJulià Blanco ArbuésJulián Eslava CampoJúlia Albó DelgadoLaia Bernad RosaLaia Vives AdriánLaura Planells FerrerLidia Garrido SanzLidia Ruiz TabuencaLluís Revilla SanchoLourdes Grau ParéLucía Gutiérrez ChamorroLucía Gómez EspadaMacedonia Trigueros PeñaManel Garcia de la FuenteMarc Noguera i JulianMaria Casadellà FontdevilaMaria Nevot BanúsMaria Salgado BernalMarina Pino CebriánMariona Parera SallentMarissa Flores SantamaríaMarta Massanella LunaMarta Navarro GutiérrezMarta Ruiz RiolMaría Lázaro DíezMiguel Marín LópezMiguel Ángel Martínez de la SierraMireia Martínez GameroMª Carmen García GuerreroMª Carmen Puertas CastroMª Luisa Rodríguez de la ConcepciónNatàlia Marrugat VilaNuria Izquierdo UserosNúria de la Iglesia ZaragozaNúria Pedreño LópezPatricia Piñol JuradoPatricia Resa InfantePenélope Riquelme NevadoPep Coll VerdRafaela Ayen AparicioRaúl Pérez CaballeroRita Casas CostaRoger Badia CórcolesRoger ParedesRosina Malagrida EscalasRuth Peña PoderósRytis BoreikaSamandhy Cedeño BriceñoSandra Franco CireraSandra Silva ArrietaSara Cabrero de las HerasSara Morón LópezSilvia Marfil VerchiliSonia Bange SinghSusana Esteban RayaSílvia Ribó GenéTeresa Puig OlivaTetyana PidkovaToni Navarro AlcarazTuixent Escribà BelValentina Triviño VenceVíctor Urrea GalesÁngel Bayón Gil From date To date RBD Dimer recombinant protein vaccine against SARS-CoV-2 Project status Ongoing Start/End 2021 / 2024 Principal investigator Marta Ruiz Riol Julià Blanco Arbués Christian Brander Jorge Carrillo Molina Samandhy Cedeño Briceño Julia García Prado Nuria Izquierdo Useros Tuixent Escribà Bel Eulalia Grau Segú Beatriz Mothe Pujadas Strategic lines Cancer Emerging infectious diseases Financing entity European Commission Codi: 101046118 In vitro antiviral screening of compounds provided by Pharma Mar on Ebola virus entry and on the replication of HIV-1, Zika and SARS-CoV-2 Project status Ongoing Start/End 2021 / 2022 Principal investigator Ester Ballana Guix Nuria Izquierdo Useros Participating entities IrsiCaixa Strategic lines Cancer Emerging infectious diseases Financing entity PharmaMar New antiviral and immunomodulatory therapies against SARS-CoV-2 Project status Ongoing Start/End 2021 / 2024 Principal investigator Nuria Izquierdo Useros Participating entities IrsiCaixa Strategic lines Cancer Emerging infectious diseases Financing entity Spanish Ministry of Science and Innovation Assessment of the antiviral activity against SARS-CoV-2 of certain mouthwashes Project status Ongoing Start/End 2021 / 2022 Principal investigator Nuria Izquierdo Useros Participating entities IrsiCaixa Strategic lines Cancer Emerging infectious diseases Financing entity DENTAID S.L. Antivirals for SARS-CoV-2 Project status Ongoing Start/End 2020 / 2021 Principal investigator Nuria Izquierdo Useros Strategic lines Cancer Emerging infectious diseases Financing entity ABIVAX Novel antiviral approaches against SARS-CoV-2 Project status Ongoing Start/End 2020 / 2021 Principal investigator Nuria Izquierdo Useros Strategic lines Cancer Emerging infectious diseases Financing entity Dentaid Novel inhibitors of the inflammasome for the mitigation of SARS-CoV-2 pathogenic effects in human type II pneumocytes and transgenic mouse models Project status Ongoing Start/End 2020 / 2021 Principal investigator Nuria Izquierdo Useros Participating entities Consejo Superior de Investigaciones Científicas (CSIC), Institut d'Investigacions Biomèdiques de Barcelona IIBB (Barcelona), Mount Sinai-Icahn School of Medicine (New York) Strategic lines Cancer Emerging infectious diseases Financing entity Proyectos de investigación sobre el SARS-CoV-2 y la enfermedad COVID19 del ISCIII Glycoengineering nanovehicles to purge viral reservoirs Project status Ongoing Start/End 2018 / 2021 Principal investigator Nuria Izquierdo Useros Participating entities ICN2 and Biofisika-CISC Financing entity Spanish Ministry of Economy and Competitiveness, ref. SAF2017-91767-EXP. Fostering prophylactic and therapeutic strategies to fight the SARS-CoV-2 pandemic Project status Ongoing Start/End 2020 / 2022 Principal investigator Bonaventura Clotet Sala Julià Blanco Arbués Jorge Carrillo Molina Nuria Izquierdo Useros Participating entities Barcelona Supercomputing Center (BSC), Animal Health Research Center (IRTA-CReSA) Financing entity Grifols Antiviral activity of Aplidin Project status Ongoing Start/End 2020 / 2021 Principal investigator Nuria Izquierdo Useros Participating entities IrsiCaixa, Animal Health Research Center (IRTA-CReSA) Financing entity Pharma Mar
RBD Dimer recombinant protein vaccine against SARS-CoV-2 Project status Ongoing Start/End 2021 / 2024 Principal investigator Marta Ruiz Riol Julià Blanco Arbués Christian Brander Jorge Carrillo Molina Samandhy Cedeño Briceño Julia García Prado Nuria Izquierdo Useros Tuixent Escribà Bel Eulalia Grau Segú Beatriz Mothe Pujadas Strategic lines Cancer Emerging infectious diseases Financing entity European Commission Codi: 101046118
In vitro antiviral screening of compounds provided by Pharma Mar on Ebola virus entry and on the replication of HIV-1, Zika and SARS-CoV-2 Project status Ongoing Start/End 2021 / 2022 Principal investigator Ester Ballana Guix Nuria Izquierdo Useros Participating entities IrsiCaixa Strategic lines Cancer Emerging infectious diseases Financing entity PharmaMar
New antiviral and immunomodulatory therapies against SARS-CoV-2 Project status Ongoing Start/End 2021 / 2024 Principal investigator Nuria Izquierdo Useros Participating entities IrsiCaixa Strategic lines Cancer Emerging infectious diseases Financing entity Spanish Ministry of Science and Innovation
Assessment of the antiviral activity against SARS-CoV-2 of certain mouthwashes Project status Ongoing Start/End 2021 / 2022 Principal investigator Nuria Izquierdo Useros Participating entities IrsiCaixa Strategic lines Cancer Emerging infectious diseases Financing entity DENTAID S.L.
Antivirals for SARS-CoV-2 Project status Ongoing Start/End 2020 / 2021 Principal investigator Nuria Izquierdo Useros Strategic lines Cancer Emerging infectious diseases Financing entity ABIVAX
Novel antiviral approaches against SARS-CoV-2 Project status Ongoing Start/End 2020 / 2021 Principal investigator Nuria Izquierdo Useros Strategic lines Cancer Emerging infectious diseases Financing entity Dentaid
Novel inhibitors of the inflammasome for the mitigation of SARS-CoV-2 pathogenic effects in human type II pneumocytes and transgenic mouse models Project status Ongoing Start/End 2020 / 2021 Principal investigator Nuria Izquierdo Useros Participating entities Consejo Superior de Investigaciones Científicas (CSIC), Institut d'Investigacions Biomèdiques de Barcelona IIBB (Barcelona), Mount Sinai-Icahn School of Medicine (New York) Strategic lines Cancer Emerging infectious diseases Financing entity Proyectos de investigación sobre el SARS-CoV-2 y la enfermedad COVID19 del ISCIII
Glycoengineering nanovehicles to purge viral reservoirs Project status Ongoing Start/End 2018 / 2021 Principal investigator Nuria Izquierdo Useros Participating entities ICN2 and Biofisika-CISC Financing entity Spanish Ministry of Economy and Competitiveness, ref. SAF2017-91767-EXP.
Fostering prophylactic and therapeutic strategies to fight the SARS-CoV-2 pandemic Project status Ongoing Start/End 2020 / 2022 Principal investigator Bonaventura Clotet Sala Julià Blanco Arbués Jorge Carrillo Molina Nuria Izquierdo Useros Participating entities Barcelona Supercomputing Center (BSC), Animal Health Research Center (IRTA-CReSA) Financing entity Grifols
Antiviral activity of Aplidin Project status Ongoing Start/End 2020 / 2021 Principal investigator Nuria Izquierdo Useros Participating entities IrsiCaixa, Animal Health Research Center (IRTA-CReSA) Financing entity Pharma Mar